{"id":170800,"date":"2023-08-28T21:22:24","date_gmt":"2023-08-29T02:22:24","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/08\/aspen-neuroscience-gears-up-for-parkinsons-trial-with-digital-health-monitoring-collab"},"modified":"2023-08-28T21:22:24","modified_gmt":"2023-08-29T02:22:24","slug":"aspen-neuroscience-gears-up-for-parkinsons-trial-with-digital-health-monitoring-collab","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/08\/aspen-neuroscience-gears-up-for-parkinsons-trial-with-digital-health-monitoring-collab","title":{"rendered":"Aspen Neuroscience gears up for Parkinson\u2019s trial with digital health monitoring collab"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/aspen-neuroscience-gears-up-for-parkinsons-trial-with-digital-health-monitoring-collab2.jpg\"><\/a><\/p>\n<p>Personalized regenerative medicine company <a href=\"https:\/\/aspenneuroscience.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Aspen Neuroscience<\/a> has joined forces with Emerald Innovations and Rune Labs to integrate digital health monitoring technology into its Trial Ready Screening Cohort Study. The study, which began in 2022, seeks to identify potential patient candidates for a future clinical trial of Aspen\u2019s personalized cell therapy (ANPD001) in Parkinson\u2019s disease.<\/p>\n<p>Aspen\u2019s approach targets Parkinson\u2019s disease by replenishing lost dopamine neurons, addressing both motor and non-motor symptoms of the disease. By combining cutting-edge biosensors, software analytics, and cellular therapies, the new collaboration aims to significantly improve the quality of life for those living with Parkinson\u2019s disease.<\/p>\n<p>Harnessing the capabilities of Emerald Innovations\u2019 \u2018invisible\u2019 off-body sensors and Rune Labs\u2019 precision neurology software, Aspen intends to bolster the collection of objective measures of motor function. The company says the partnership will enable long-term symptom capture, providing useful data on disease progression before treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Personalized regenerative medicine company Aspen Neuroscience has joined forces with Emerald Innovations and Rune Labs to integrate digital health monitoring technology into its Trial Ready Screening Cohort Study. The study, which began in 2022, seeks to identify potential patient candidates for a future clinical trial of Aspen\u2019s personalized cell therapy (ANPD001) in Parkinson\u2019s disease. Aspen\u2019s [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,269,47],"tags":[],"class_list":["post-170800","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-life-extension","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=170800"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/170800\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=170800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=170800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=170800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}